Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD3 x Anti-EGFR BATs in Advanced Pancreatic Cancer
NCT02620865Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Dec 2015
- Primary completion
- Jun 2021
- Modality
- Bispecific Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of EGFR BATs in pancreatic adenocarcinoma (PDAC), sponsored by Barbara Ann Karmanos Cancer Institute. Started Dec 2015; status: completed.
02
Drugs
EGFR BATs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02620865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620865.